Experts from Quest Diagnostics will highlight data from 13 studies on a range of laboratory topics at the 2026 Association for Diagnostics & Laboratory Medicine’s (ADLM) Annual Meeting, July 26-30, 2026 in Anaheim, California. The studies cover a range of the company’s clinical focus areas, including cardiometabolic and endocrinology, infectious disease and immunology, neurology, prescription drug monitoring and toxicology, and oncology. 

“At Quest Diagnostics, we believe that laboratory testing is at the center of healthcare, providing insights to make health more proactive, personal, and connected,” said board-certified oncologist, pathologist and internist Dr. Yuri Fesko, Senior Vice President and Chief Medical Officer, Quest Diagnostics. “ADLM is the lab industry’s premier conference, and we look forward to sharing our findings based on our innovations and unique visibility into the nation’s health.”  

In addition to the new research, Wen Dui, Associate Director of R&D Toxicology, Quest Diagnostics, will host a roundtable discussion titled “Emerging Environmental Toxins: PFAS Forever Chemicals and Beyond” on July 27 from 7:30 – 8:30 am and 12:30 – 1:30 pm P.T.    Posters being presented by Quest researchers:  

Cardiometabolic and Endocrinology 

• Comparison of the 2021 CKD EPI Creatinine-Cystatin C eGFR Refit to the 2012 CKD-EPI Cystatin C and the 2021 2012 CKD-EPI Creatinine eGFR Refit for Assessment of Kidney Disease; Kristin Mullins (Poster B-288, July 29, 1:30pm-2:30pm PT) 

Infectious Disease 

• Comparison of BioFire and Verigene Blood Culture Tests for Identification of Polymicrobial Gram-Positive/Gram-Negative Cultures; George Pratt (Poster A-101, July 28, 1:30pm-2:30pm PT) 

Neurology 

• High-Throughput LC-MS/MS Assay for Quantitation of Glial Fibrillary Acidic Protein (GFAP) in Plasma; Shelby Jiyeon Ahn (Poster: B-329, July 29, 1:30pm-2:30pm PT) 
• IGF-2/IGF-1 Ratio is Associated with Plasma Amyloid Biomarkers in Alzheimer’s Disease: Possible Evidence of Modulation of Amyloid Biology; Nima Hosseini Jazani (Poster B-332, July 29, 1:30pm-2:30pm PT) 

Oncology 

• Establishing Measurement Uncertainty for Tumor Markers: Impact of Analytical Variation in Quality control Material vs. Patient Serum Matrix; Vivek Kumar (Poster: B-093, July 29, 1:30pm-2:30pm PT) 

Prescription Drug Monitoring/Toxicology  

• Associations of Serum Per- an Polyfluoroalkyl Substances (PFAS) Levels with Clinical Indicators in a Clinical Patient Cohort; Wen Dui (Poster: B-382, July 29, 1:30pm-2:30pm PT) 
  • Winner of Best Abstracts Submitted in TDMTOX Division (1 of 5) 
• Comparative Evaluation of Benzodiazepines Positivity Rates in Serum and Urine by LC-MS/MS; Victoria Zhe Cheng (Poster: B-381, July 29, 1:30pm-2:30pm PT) 
• Development and Validation of a High-throughput LC-MS/MS Method for Routine Monitoring of Benzodiazepines in Serum; Thomas W. Gorewich (Poster: B-383, July 29, 1:30pm-2:30pm PT) 
• The Determination of Mitragynine in Human Urine by Liquid Chromatography Tandem Mass Spectrometry; Bing Pang (Poster: B-331, July 29, 1:30pm-2:30pm PT) 
• Cross-reactivity of Designer Benzodiazepines in point-care Urine Drug Screening Cups; Jilian Neifeld (Poster: B-385, July 29, 1:30pm-2:30pm PT)  
• Gabapentin Positive Urine Specimens and Detection of Opioids; Lixia Chen (Poster B-380, July 29, 1:30pm-2:30pm PT) 
• Hydrolysis of Clinical Urine Specimens for Monitoring Nicotine Use; Taylor Hunt (Poster B-384, July 29, 1:30pm-2:30pm PT) 
• A Definitive High-Throughput Assay for Cyclobenzaprine, Norcyclobenzaprine, Dextromethorphan, and Dextrorphan in Urine; Anita Dermartirosian (Poster B-330, July 29, 1:30pm-2:30pm PT)